Trial · NCT07908147
Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study
NCT07908147, Early phase 1, Not yet recruiting, Olivia Newton-John Cancer Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study. Trials, record NCT07908147. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908147
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study
- NCT number
- NCT07908147
- Status
- Not yet recruiting
- Phases
- Early phase 1
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Olivia Newton-John Cancer Research Institute
- Conditions
- IDH Wildtype Glioblastoma, Glioblastoma (GBM)
- Interventions
- Larotrectinib, Cadonilimab, Plixorafenib
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility of Rapid Molecular Profiling and Matched Targeted Therapy | From enrollment to initiation of chemoradiation (pre-treatment period). | To assess the feasibility of performing rapid molecular profiling before chemoradiation and initiating matched targeted therapy in patients with actionable molecular alterations. |
| Secondary | Number and Percentage of Participants Experiencing Adverse Events by CTCAE Grade | From Cycle 1 Day 1 (each cycle is 28 days) until 30 days after the end of study treatment. | Toxicity of treatment with plixorafenib, cadonilimab, or larotrectinib will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0. The number and percentage of participants experiencing adverse events will be summarized by CTCAE severity grade and, where applicable, relationship to study treatment. |
| Secondary | Efficacy of Induction Targeted Therapy in Newly Diagnosed Glioblastoma | From Cycle 1 Day 1 (each cycle is 28 days) until the commencement of the next anti-cancer intervention or death from any cause, whichever occurs first. | To assess the efficacy of induction treatment with plixorafenib, cadonilimab, or larotrectinib in patients with newly diagnosed glioblastoma and eligible molecular profiles, measured by progression-free survival (PFS) and time to next intervention (TTNI) |
| Secondary | Change in Quality of Life Scores as Assessed by the EORTC QLQ-C30 Questionarrie | From Cycle 1 Day 1 (each cycle is 28 days) through the end of treatment (EOT), up to 12 months. | The effect of upfront treatment with plixorafenib, cadonilimab, or larotrectinib on quality of life in patients with newly diagnosed glioblastoma with eligible molecular phenotypes will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores will be calculated according to the questionnaire scoring manual. |
| Secondary | Change in Learning and Memory Scores as Assessed by the Hopkins Verbal Learning Test-Revised (HVLT-R) | At baseline (before initiation of study drugs or standard chemoradiation) and every 12 months thereafter, up to 5 years after initial surgery at diagnosis. | Neurocognitive function in patients with newly diagnosed glioblastoma and eligible molecular profiles will be assessed using the Hopkins Verbal Learning Test-Revised (HVLT-R), which evaluates verbal learning and memory. |
| Secondary | Change in Quality of Life Scores as Assessed by the EORTC QLQ-BN20 Questionarrie | From Cycle 1 Day 1 (each cycle is 28 days) through the end of treatment (EOT), up to 12 months. | The effect of upfront treatment with plixorafenib, cadonilimab, or larotrectinib on brain tumour-specific quality of life in patients with newly diagnosed glioblastoma with eligible molecular phenotypes will be assessed using the European Organisation for Research and Treatment of Cancer Brain Neoplasm Module (EORTC QLQ-BN20). Scores will be calculated according to the questionnaire scoring manual. |
| Secondary | Change in Attention and Working Memory Scores as Assessed by the Wechsler Adult Intelligence Scale Digit Span Test | At baseline (before initiation of study drugs or standard chemoradiation) and every 12 months thereafter, up to 5 years after initial surgery at diagnosis. | Attention and working memory will be assessed using the Digit Span subtest of the Wechsler Adult Intelligence Scale (WAIS). Changes in scores from baseline will be summarized over the assessment period. |
| Secondary | Change in Processing Speed as Assessed by Trail Making Test Part A | At baseline (before initiation of study drugs or standard chemoradiation) and every 12 months thereafter, up to 5 years after initial surgery at diagnosis. | Processing speed will be assessed using Trail Making Test Part A. Changes in test performance from baseline will be summarized over the assessment period. |
| Secondary | Change in Executive Function as Assessed by Verbal Fluency and Trail Making Test Part B | At baseline (before initiation of study drugs or standard chemoradiation) and every 12 months thereafter, up to 5 years after initial surgery at diagnosis. | Executive function will be assessed using verbal fluency testing and Trail Making Test Part B. Changes in test performance from baseline will be summarized over the assessment period. |
| Other | Overall Survival | From Cycle 1 Day 1 (each cycle is 28 days) until death from any cause or the end of the study follow-up period for a maximum of 5 years. | Overall survival is defined as the time from Cycle 1 Day 1 (C1D1) to death from any cause. Overall survival will be summarized using the Kaplan-Meier method, with median overall survival and corresponding 95% confidence intervals reported, as applicable. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908147
GET https://conductscience.org/api/trials/v1/NCT07908147/registered